Comparison of efficacy between sodium morrhuate and lauromacrogol as sclerosing agents in treatment of hepatic cyst
10.3969/j.issn.1001-5256.2015.07.026
- VernacularTitle:鱼肝油酸钠与聚桂醇硬化治疗肝囊肿的疗效对比
- Author:
Zuyun QIN
1
;
Yabing GUO
Author Information
1. Department of Liver Disease, Guidong People′s Hospital, Wuzhou, Guangxi 543001, China
- Publication Type:Research Article
- Keywords:
liver cyst;
lauromacrogol;
sodium morrhuate;
sclerotherapy
- From:
Journal of Clinical Hepatology
2015;31(7):1107-1109
- CountryChina
- Language:Chinese
-
Abstract:
ObjectiveTo compare the efficacy of sodium morrhuate versus lauromacrogol in the treatment of hepatic cyst. MethodsSeventy-four patients with hepatic cyst who were admitted to our hospital from January 2009 to May 2013 were enrolled as subjects and divided into two groups. After the cystic fluid was drained by percutaneous liver biopsy, sodium morrhuate solution was injected into the cystic cavity for adhesion and sclerosis in 46 patients in group A, and lauromacrogol solution was injected in 28 patients in group B. The incidence rates of pain in patients during and after surgery were compared between the two groups. The follow-up comparison of hepatic cyst recurrence rates within one year after surgery was performed between the two groups. Between-group comparison was performed by χ2 test. ResultsFive patients (10.87%) in group A and two patients (7.14%) in group B had recurrence within one year after treatment. There was no significant difference in recurrence rate between the two groups (χ2=0.283, P＞0.05). The incidence of pain in group A was significantly higher than that in group B (χ2=5.258, P＜0.05). ConclusionWith the same efficacy as sodium morrhuate in the treatment of hepatic cyst, lauromacrogol can be routinely used as a sclerosing agent due to its mild side effects.
